View Older Stories View More Recent Stories

Dec 8, 2022 08:00AM Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Nov 28, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Nov 21, 2022 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 14, 2022 04:30PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
Nov 9, 2022 08:11AM Arrowhead Pharmaceuticals (ARWR) Sells Royalty Interest in Olpasiran to Royalty Pharma (RPRX) for $250 Million and Future Milestones
Nov 9, 2022 08:10AM Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Nov 7, 2022 04:09PM Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data
Nov 7, 2022 04:08PM Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Oct 13, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 11, 2022 07:30AM Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Sep 1, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Aug 17, 2022 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 17, 2022 07:30AM Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 4, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Jul 20, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
Jul 8, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 5, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
Jun 27, 2022 06:02AM Takeda Pharmaceutical (TAK) and Arrowhead (ARWR) Announce Publication of Results from Phase 2 Study of Fazirsiran
Jun 27, 2022 06:00AM Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Jun 7, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
May 26, 2022 07:30AM Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 10, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 9, 2022 10:30AM Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 2, 2022 07:33AM Arrowhead Pharmaceuticals (ARWR) Appoints Victoria Vakiener to its Board
May 2, 2022 07:31AM Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 2, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
Apr 27, 2022 07:30AM Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
Apr 26, 2022 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Commences Phase 2 GATEWAY Study of Investigational ARO-ANG3
Apr 26, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Apr 25, 2022 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Apr 25, 2022 07:30AM Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Apr 20, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
Apr 6, 2022 07:30AM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Apr 1, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
Mar 24, 2022 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Cleared to Initiate Phase 1/2a Study of ARO-MUC5AC
Mar 24, 2022 07:30AM Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Mar 15, 2022 07:31AM Arrowhead (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Mar 15, 2022 07:30AM Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Feb 24, 2022 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3
Feb 24, 2022 07:30AM Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
Feb 18, 2022 07:32AM Arrowhead Pharmaceuticals (ARWR) Commences Phase 1/2 Study of ARO-C3
Feb 18, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Feb 17, 2022 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports New Clinical Data on ARO-HIF2
Feb 17, 2022 07:30AM Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
Feb 2, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
Jan 21, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
Jan 12, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Dec 20, 2021 07:30AM Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
Dec 17, 2021 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2021 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
View More Recent Stories View Older Stories